The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Gilead has become the latest pharma to strengthen its in-vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. | Gilead has become the latest ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead Sciences is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic ...